APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Vaginal Atrophy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast 2026-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchPostmenopausal Vaginal Atrophy Drugs Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Vaginal Atrophy Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Postmenopausal Vaginal Atrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Vaginal Atrophy Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Postmenopausal Vaginal Atrophy Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Postmenopausal Vaginal Atrophy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Postmenopausal Vaginal Atrophy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Postmenopausal Vaginal Atrophy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Postmenopausal Vaginal Atrophy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Postmenopausal Vaginal Atrophy Drugs include Teva Pharmaceutical Industries, Novo Nordisk, Pfizer, Millicent Pharma, Endoceutics, Duchesnay USA and Aspen Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Postmenopausal Vaginal Atrophy Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Postmenopausal Vaginal Atrophy Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Postmenopausal Vaginal Atrophy Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Postmenopausal Vaginal Atrophy Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Postmenopausal Vaginal Atrophy Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Postmenopausal Vaginal Atrophy Drugs sales, projected growth trends, production technology, application and end-user industry.

Postmenopausal Vaginal Atrophy Drugs Segment by Company

Teva Pharmaceutical Industries

Novo Nordisk

Pfizer

Millicent Pharma

Endoceutics

Duchesnay USA

Aspen Pharma

Postmenopausal Vaginal Atrophy Drugs Segment by Type

Tablets

Suppositories

Creams

Rings

Postmenopausal Vaginal Atrophy Drugs Segment by Application

Offline Stores

Online Stores

Postmenopausal Vaginal Atrophy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Vaginal Atrophy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Vaginal Atrophy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Vaginal Atrophy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Postmenopausal Vaginal Atrophy Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Postmenopausal Vaginal Atrophy Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tablets Major Manufacturers Table 3. Suppositories Major Manufacturers Table 4. Creams Major Manufacturers Table 5. Rings Major Manufacturers Table 6. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Offline Stores Major Manufacturers Table 8. Online Stores Major Manufacturers Table 9. Postmenopausal Vaginal Atrophy Drugs Industry Trends Table 10. Postmenopausal Vaginal Atrophy Drugs Industry Drivers Table 11. Postmenopausal Vaginal Atrophy Drugs Industry Opportunities and Challenges Table 12. Postmenopausal Vaginal Atrophy Drugs Industry Restraints Table 13. Global Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2021-2026) Table 17. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2027-2032) Table 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021-2026) & (k units) Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2027-2032) & (k units) Table 21. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2021-2026) Table 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2027-2032) Table 23. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Postmenopausal Vaginal Atrophy Drugs Sales Price (US$/unit) of Manufacturers (2021-2026) Table 28. Global Postmenopausal Vaginal Atrophy Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Postmenopausal Vaginal Atrophy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers, Product Type & Application Table 31. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Postmenopausal Vaginal Atrophy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2021-2026) Table 38. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2027-2032) Table 39. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 41. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 42. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2021-2026) Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2027-2032) Table 44. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2021-2026) & (US$/unit) Table 45. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2027-2032) & (US$/unit) Table 46. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2021-2026) Table 50. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2027-2032) Table 51. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 53. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 54. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2021-2026) Table 55. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2027-2032) Table 56. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2021-2026) & (US$/unit) Table 57. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2027-2032) & (US$/unit) Table 58. Teva Pharmaceutical Industries Company Information Table 59. Teva Pharmaceutical Industries Business Overview Table 60. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 62. Teva Pharmaceutical Industries Recent Development Table 63. Novo Nordisk Company Information Table 64. Novo Nordisk Business Overview Table 65. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 67. Novo Nordisk Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Pfizer Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 72. Pfizer Recent Development Table 73. Millicent Pharma Company Information Table 74. Millicent Pharma Business Overview Table 75. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 77. Millicent Pharma Recent Development Table 78. Endoceutics Company Information Table 79. Endoceutics Business Overview Table 80. Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Endoceutics Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 82. Endoceutics Recent Development Table 83. Duchesnay USA Company Information Table 84. Duchesnay USA Business Overview Table 85. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 87. Duchesnay USA Recent Development Table 88. Aspen Pharma Company Information Table 89. Aspen Pharma Business Overview Table 90. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 92. Aspen Pharma Recent Development Table 93. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 94. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 95. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 96. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 97. North America Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 98. North America Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 99. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 100. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 101. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 102. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 103. North America Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 104. North America Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 105. North America Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. North America Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 107. North America Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 108. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 109. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 110. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 111. North America Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 112. North America Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 113. United States Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 114. Canada Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 115. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 116. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 117. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 118. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 119. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 120. Europe Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 121. Europe Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 122. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 123. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 124. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 125. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 126. Europe Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 127. Europe Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 128. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 130. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 131. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 132. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 133. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 134. Europe Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 135. Europe Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 136. Germany Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 137. France Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 138. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 139. Italy Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 140. Russia Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 141. Spain Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 142. Netherlands Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 143. Switzerland Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 144. Sweden Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 145. Poland Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 146. China Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. China Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. China Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 149. China Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 150. China Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 151. China Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 152. China Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 153. China Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 154. China Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 155. China Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 156. China Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 157. China Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 158. Asia Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 159. Asia Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 160. Asia Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 161. Asia Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 162. Asia Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 163. Asia Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 164. Asia Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 165. Asia Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 166. Asia Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 167. Asia Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 168. Asia Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 169. Asia Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 170. Asia Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. Asia Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. Asia Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. Asia Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 174. Asia Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 175. Asia Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 176. Asia Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 177. Asia Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 178. Japan Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 179. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 180. India Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 181. Australia Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 182. Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 183. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 184. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 185. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 186. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 187. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 188. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2021-2026) & (US$/unit) Table 189. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Price by Type (2027-2032) & (US$/unit) Table 190. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 191. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 192. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 193. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 194. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2021-2026) & (US$/unit) Table 195. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Price by Application (2027-2032) & (US$/unit) Table 196. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 200. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 201. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Country (2027-2032) & (k units) Table 202. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2021-2026) & (US$/unit) Table 203. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Price by Country (2027-2032) & (US$/unit) Table 204. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 205. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 206. Chile Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 207. Colombia Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 208. Peru Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 209. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 210. Israel Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 211. UAE Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 212. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 213. Iran Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 214. Egypt Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Table 215. Key Raw Materials Table 216. Raw Materials Key Suppliers Table 217. Postmenopausal Vaginal Atrophy Drugs Distributors List Table 218. Postmenopausal Vaginal Atrophy Drugs Customers List Table 219. Research Programs/Design for This Report Table 220. Authors List of This Report Table 221. Secondary Sources Table 222. Primary Sources List of Figures Figure 1. Postmenopausal Vaginal Atrophy Drugs Image Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tablets Image Figure 5. Suppositories Image Figure 6. Creams Image Figure 7. Rings Image Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Postmenopausal Vaginal Atrophy Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Offline Stores Image Figure 11. Online Stores Image Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2021-2032) Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Sales (2021-2032) & (k units) Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Postmenopausal Vaginal Atrophy Drugs Sales YoY (2021-2032) & (k units) Figure 21. Europe Postmenopausal Vaginal Atrophy Drugs Sales YoY (2021-2032) & (k units) Figure 22. China Postmenopausal Vaginal Atrophy Drugs Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Postmenopausal Vaginal Atrophy Drugs Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales YoY (2021-2032) & (k units) Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2021-2032) Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2021-2032) Figure 34. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2021-2032) Figure 37. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2021-2032) Figure 40. North America Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2021-2032) Figure 41. North America Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2032) Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2021-2032) Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2032) Figure 44. North America Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country (2021-2032) Figure 45. North America Postmenopausal Vaginal Atrophy Drugs Sales Share by Country (2021-2032) Figure 46. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2021-2032) Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2032) Figure 48. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2021-2032) Figure 49. Europe Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2032) Figure 50. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country (2021-2032) Figure 51. Europe Postmenopausal Vaginal Atrophy Drugs Sales Share by Country (2021-2032) Figure 52. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2021-2032) Figure 53. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2032) Figure 54. China Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2021-2032) Figure 55. China Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2032) Figure 56. Asia Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2021-2032) Figure 57. Asia Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2032) Figure 58. Asia Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2021-2032) Figure 59. Asia Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2032) Figure 60. Asia Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country (2021-2032) Figure 61. Asia Postmenopausal Vaginal Atrophy Drugs Sales Share by Country (2021-2032) Figure 62. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2021-2032) Figure 64. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2021-2032) Figure 65. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2021-2032) Figure 66. SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue Share by Country (2021-2032) Figure 67. SAMEA Postmenopausal Vaginal Atrophy Drugs Sales Share by Country (2021-2032) Figure 68. Postmenopausal Vaginal Atrophy Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Postmenopausal Vaginal Atrophy Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Suppositories
  • Creams
  • Rings
Applications
  • Offline Stores
  • Online Stores
Companies covered
  • Teva Pharmaceutical Industries
  • Novo Nordisk
  • Pfizer
  • Millicent Pharma
  • Endoceutics
  • Duchesnay USA
  • Aspen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Postmenopausal Vaginal Atrophy Drugs Market by Type
  3. 1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tablets
  5. 1.2.3 Suppositories
  6. 1.2.4 Creams
  7. 1.2.5 Rings
  8. 1.3 Postmenopausal Vaginal Atrophy Drugs Market by Application
  9. 1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Offline Stores
  11. 1.3.3 Online Stores
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Postmenopausal Vaginal Atrophy Drugs Market Dynamics
  1. 2.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
  2. 2.2 Postmenopausal Vaginal Atrophy Drugs Industry Drivers
  3. 2.3 Postmenopausal Vaginal Atrophy Drugs Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Vaginal Atrophy Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region
  3. 3.2.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region
  9. 3.4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
  2. 4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
  6. 4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Postmenopausal Vaginal Atrophy Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Postmenopausal Vaginal Atrophy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Postmenopausal Vaginal Atrophy Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Postmenopausal Vaginal Atrophy Drugs Market CR5 and HHI
  16. 4.8.2 2025 Postmenopausal Vaginal Atrophy Drugs Tier 1, Tier 2, and Tier 3
5 Postmenopausal Vaginal Atrophy Drugs Market by Type
  1. 5.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type
  2. 5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type
  6. 5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type
6 Postmenopausal Vaginal Atrophy Drugs Market by Application
  1. 6.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application
  2. 6.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application
  6. 6.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries
  2. 7.1.1 Teva Pharmaceutical Industries Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 7.2 Novo Nordisk
  8. 7.2.1 Novo Nordisk Company Information
  9. 7.2.2 Novo Nordisk Business Overview
  10. 7.2.3 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  12. 7.2.5 Novo Nordisk Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Millicent Pharma
  20. 7.4.1 Millicent Pharma Company Information
  21. 7.4.2 Millicent Pharma Business Overview
  22. 7.4.3 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  24. 7.4.5 Millicent Pharma Recent Developments
  25. 7.5 Endoceutics
  26. 7.5.1 Endoceutics Company Information
  27. 7.5.2 Endoceutics Business Overview
  28. 7.5.3 Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Endoceutics Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  30. 7.5.5 Endoceutics Recent Developments
  31. 7.6 Duchesnay USA
  32. 7.6.1 Duchesnay USA Company Information
  33. 7.6.2 Duchesnay USA Business Overview
  34. 7.6.3 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  36. 7.6.5 Duchesnay USA Recent Developments
  37. 7.7 Aspen Pharma
  38. 7.7.1 Aspen Pharma Company Information
  39. 7.7.2 Aspen Pharma Business Overview
  40. 7.7.3 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  42. 7.7.5 Aspen Pharma Recent Developments
8 North America
  1. 8.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Type
  2. 8.1.1 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Postmenopausal Vaginal Atrophy Drugs Price by Type (2021-2032)
  5. 8.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Application
  6. 8.2.1 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Postmenopausal Vaginal Atrophy Drugs Price by Application (2021-2032)
  9. 8.3 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  10. 8.3.1 North America Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Postmenopausal Vaginal Atrophy Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Type
  2. 9.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Postmenopausal Vaginal Atrophy Drugs Price by Type (2021-2032)
  5. 9.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Application
  6. 9.2.1 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Postmenopausal Vaginal Atrophy Drugs Price by Application (2021-2032)
  9. 9.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  10. 9.3.1 Europe Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Postmenopausal Vaginal Atrophy Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Postmenopausal Vaginal Atrophy Drugs Market Size by Type
  2. 10.1.1 China Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Postmenopausal Vaginal Atrophy Drugs Price by Type (2021-2032)
  5. 10.2 China Postmenopausal Vaginal Atrophy Drugs Market Size by Application
  6. 10.2.1 China Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Postmenopausal Vaginal Atrophy Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Postmenopausal Vaginal Atrophy Drugs Market Size by Type
  2. 11.1.1 Asia Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Postmenopausal Vaginal Atrophy Drugs Price by Type (2021-2032)
  5. 11.2 Asia Postmenopausal Vaginal Atrophy Drugs Market Size by Application
  6. 11.2.1 Asia Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Postmenopausal Vaginal Atrophy Drugs Price by Application (2021-2032)
  9. 11.3 Asia Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  10. 11.3.1 Asia Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Postmenopausal Vaginal Atrophy Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Postmenopausal Vaginal Atrophy Drugs Market Size by Type
  2. 12.1.1 SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Postmenopausal Vaginal Atrophy Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Postmenopausal Vaginal Atrophy Drugs Market Size by Application
  6. 12.2.1 SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Postmenopausal Vaginal Atrophy Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  10. 12.3.1 SAMEA Postmenopausal Vaginal Atrophy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Postmenopausal Vaginal Atrophy Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Postmenopausal Vaginal Atrophy Drugs Value Chain Analysis
  2. 13.1.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Postmenopausal Vaginal Atrophy Drugs Production Mode & Process
  6. 13.2 Postmenopausal Vaginal Atrophy Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Postmenopausal Vaginal Atrophy Drugs Distributors
  9. 13.2.3 Postmenopausal Vaginal Atrophy Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst